Merck Reports EC Approval of KEYTRUDA for Patients with Relapsed, Refractory Classical Hodgkin Lymphoma Who Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV
Paul Quintaro